Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Postprint
DOI
PMC
 |
Open Access Green |
as soon as is submitted to ZB.
Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
J. Eur. Acad. Dermatol. Venereol., DOI: 10.1111/jdv.16078 (2019)
Background The Atopic Dermatitis (AD) TREATgermany registry was initiated by the German Society for Dermatology (DDG) in 2011 to evaluate the 'real-life' situation of health care for patients with AD.Objectives Interim data analysis on baseline characteristics as well as current and prescribed systemic treatments of the TREATgermany registry patients.Methods Patients (>= 18 years) with moderate-to-severe AD [objective (o)SCORAD > 20], or with current or previous anti-inflammatory systemic treatment for AD within 24 months, were included and are followed up over at least 24 months. To assess clinical signs, the eczema area severity index (EASI, 0-72), the oSCORAD (0-83) and the Investigator Global Assessment (IGA; 6-point scale) were used. The disease severity was globally scored by the patients [Patient Global Assessment (PGA); six-step Likert scale]. Disease symptoms were assessed by the patient-oriented eczema measure (POEM, 0-28) and numeric rating scales (NRS, 0-10). Health-related quality of life was measured using the dermatological life quality index (DLQI, 0-30).Results A total of 612 patients were recruited across 32 sites between 06/2016 and 01/2019 (mean age: 42.6 +/- 14.2 years; mean oSCORAD: 40.8 +/- 16.3). The mean POEM score was 16.3 +/- 7.5. Pruritus was rated highest among subjective symptoms (NRS: 5.4 +/- 2.7). The mean DLQI value was 11.3 +/- 7.5. The frequency of arterial hypertension was lower (20.8%) compared with the general population, whilst this was higher for depression (10%). More than 60% of the patients had received systemic glucocorticosteroids, and 36.8% had received cyclosporine A prior to inclusion. Dupilumab was the leading substance documented as either 'current' (12.1%) or 'prescribed' (31.4%) at baseline.Conclusions These 'real-life' data clearly demonstrate the substantial disease burden. Most of TREATgermany patients were already treated with or prescribed dupilumab at baseline. Moreover, current findings indicate the urgent need for further alternative agents in order to achieve a perceptible improvement of quality of life of patients with moderate-to-severe AD.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
1.613
1.613
17
16
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Poem ; Comorbidity ; Dupilumab ; Oscorad ; Quality Of Life ; Systemic Treatment; Party Diagnostic-criteria; Oriented Eczema Measure; Quality-of-life; Outcome Measures; Objective Scorad; Index Easi; Adults; Consensus; Validation; Dupilumab
Language
english
Publication Year
2019
HGF-reported in Year
2019
ISSN (print) / ISBN
0926-9959
e-ISSN
1468-3083
Publisher
Wiley
Publishing Place
111 River St, Hoboken 07030-5774, Nj Usa
Reviewing status
Peer reviewed
Institute(s)
Institute for Allergy Research (IAF)
POF-Topic(s)
30503 - Chronic Diseases of the Lung and Allergies
30202 - Environmental Health
30202 - Environmental Health
Research field(s)
Allergy
PSP Element(s)
G-509000-008
G-522200-001
G-522200-001
WOS ID
WOS:000513128100001
PubMed ID
31721316
Erfassungsdatum
2020-01-10